İçeriğe geç
akaturk Akademik ölçüm

OpenAlex konusu

Complement system in diseases

Bu sayfa OpenAlex konu etiketine göre çalışmaları ve o konuda görünen akademisyenleri listeler. YÖKSİS temel alan / yan dal değildir.

OpenAlex 1.933 eser 29 yazar konusu

Çalışmalar

1.933 eser

  1. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Özet henüz yok.

  2. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 97.7%

    BACKGROUND: Studies of monogenic gastrointestinal diseases have revealed molecular pathways critical to gut homeostasis and enabled the development of targeted therapies. METHODS: We studied 11 patients with abdominal pain and diarrhea caused by early-onset protein-losing enteropathy with primary intestinal lymphangie…

  3. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 97.5%

    BACKGROUND: Studies of monogenic gastrointestinal diseases have revealed molecular pathways critical to gut homeostasis and enabled the development of targeted therapies. METHODS: We studied 11 patients with abdominal pain and diarrhea caused by early-onset protein-losing enteropathy with primary intestinal lymphangie…

  4. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 97.5%

    BACKGROUND: Studies of monogenic gastrointestinal diseases have revealed molecular pathways critical to gut homeostasis and enabled the development of targeted therapies. METHODS: We studied 11 patients with abdominal pain and diarrhea caused by early-onset protein-losing enteropathy with primary intestinal lymphangie…

  5. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 97.5%

    BACKGROUND: Studies of monogenic gastrointestinal diseases have revealed molecular pathways critical to gut homeostasis and enabled the development of targeted therapies. METHODS: We studied 11 patients with abdominal pain and diarrhea caused by early-onset protein-losing enteropathy with primary intestinal lymphangie…

  6. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.2%

    BACKGROUND: The consensus documents published to date on hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) have focused on adult patients. Many of the previous recommendations have not been adapted to pediatric patients. We intended to produce consensus recommendations for the diagnosis and management of…

  7. YÖKSİS SJR Q1 JCR Q1 OpenAlex 84.3%

    The correlation of many HLA-associated autoimmune and genetic diseases with the polymorphic complement C4 genes may be attributed to the presence of disease susceptibility genes in the close proximity of C4. We have cloned and characterized a pair of partially duplicated genes, RP1 and RP2, located 611 base pairs upst…

  8. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    BACKGROUND: The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. METHODS: In this phase 3, double-blind, randomized, placebo-controlled trial, we enrolled adults with biopsy-confirmed IgA nephropathy a…

  9. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.4%

    The lectin pathway of complement is an important component of innate immunity. Its activation has been thought to occur via recognition of pathogens by mannan-binding lectin (MBL) or ficolins in complex with MBL-associated serine protease (MASP)-2, followed by MASP-2 autoactivation and cleavage of C4 and C2 generating…

  10. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.3%

    The lectin pathway of complement is an important component of innate immunity. Its activation has been thought to occur via recognition of pathogens by mannan-binding lectin (MBL) or ficolins in complex with MBL-associated serine protease (MASP)-2, followed by MASP-2 autoactivation and cleavage of C4 and C2 generating…

  11. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 95.3%

    Özet henüz yok.

  12. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 96.0%

    Complement activation in the kidney after ischemia/reperfusion (I/R) seems to occur primarily via the alternative complement pathway. The ability of an inhibitory mAb to mouse factor B, a necessary component of the alternative pathway, to protect mice from ischemic acute renal failure was tested. Treatment with the mA…

Akademisyenler

29 akademisyen